<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00188578</url>
  </required_header>
  <id_info>
    <org_study_id>UHN REB 03-0298-C</org_study_id>
    <nct_id>NCT00188578</nct_id>
  </id_info>
  <brief_title>Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2)</brief_title>
  <official_title>A Pilot Study of Conformal Intensity Modulated Radiation Therapy (IMRT) for Gynaecological Cancer Patients Not Suitable for Intracavitary Brachytherapy Boost (GY03.2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <brief_summary>
    <textblock>
      Standard treatment for gynecological cancer is radiation therapy in two phases; whole pelvic&#xD;
      radiation and then an internal radiation boost, also called a brachytherapy boost, to treat&#xD;
      any remaining tumour.&#xD;
&#xD;
      The purpose of this study is to test an alternative radiation boost treatment called&#xD;
      conformal intensity modulated radiation therapy or IMRT. Currently, we do not have complete&#xD;
      information on the overall effectiveness of IMRT compared to brachytherapy or conformal&#xD;
      radiotherapy. We know that IMRT allows the radiation beams to be more accurately focused on&#xD;
      the tumor, thereby sparing more normal tissue from radiation damage and lowering risks of&#xD;
      side effects. We are investigating the extent to which IMRT can be used to protect normal&#xD;
      tissues in patients with cervix, uterine or vaginal cancer from the radiation beams and how&#xD;
      much the side effects of radiation are reduced.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the feasibility of using IMRT to boost the primary tumour in patients with gynecological cancers who are unsuitable for brachytherapy.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the acute and late toxicity of IMRT boost.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate tumour response and patient survival data.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cervix Neoplasms</condition>
  <condition>Uterine Neoplasms</condition>
  <condition>Vaginal Neoplasms</condition>
  <arm_group>
    <arm_group_label>IMRT Gynecological Cancers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intensity Modulated Radiation Therapy Boost</intervention_name>
    <description>All patients shall receive a continuous course of IMRT consisting of 25.2 Gy in 14 fractions over 3 weeks</description>
    <arm_group_label>IMRT Gynecological Cancers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy-proven carcinoma of the cervix, uterus or vagina; FIGO stage T1B-4A, NO/1, MO,&#xD;
             treated with definitive radiotherapy with or without chemotherapy, or Biopsy-proven&#xD;
             pelvic recurrence of carcinoma of the uterus previously untreated or biopsy-proven&#xD;
             vaginal carcinoma treated radically with radiotherapy but unsuitable for brachytherapy&#xD;
             boost.&#xD;
&#xD;
          -  Patients not suitable for intracavitary brachytherapy.&#xD;
&#xD;
          -  ECOG performance status of 0, 1, or 2&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Ability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Fyles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Milosevic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Princess Margaret Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>February 8, 2016</last_update_submitted>
  <last_update_submitted_qc>February 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

